Australian News
Aspen Announces Multi-Territory Acquisition Of GSK OTC Products
Australian News, New Zealand News, Media Release
Aspen has acquired a range of OTC products from GSK in a multi-territory transaction.
For Australia, the basket of products has sales of around $17 million, with about $750K in New Zealand. Other Asia-Pacific countries coming under the Aspen Australia umbrella represent sales of around $13.5 million.
The products in Australia are Cartia, Zantac, Lipeze, Quellada and Beconase, all well known power brands which will cement the position of Aspen Australia as one of the leading OTC companies in the country.
Aspen Launch Philippines Business
Australian News, New Zealand News, Media Release
Aspen, Africa’s largest pharmaceutical manufacturer and the biggest listed pharmaceutical group in the health care sector of the Johannesburg Stock Exchange, through Aspen Pharmacare Australia, one of the leading pharmaceutical companies in Australia, aims to make high-quality branded medicine available to Filipino patients at affordable cost through the launch of its local subsidiary, Aspen Philippines.
Australian Packaging Covenant - Aspen Report
Australian News, Media Release
The Australian Packaging Covenant is a voluntary initiative by Government and Industry to reduce the environmental effects of packaging. It is designed to minimise the environmental impacts arising from the disposal of used packaging, conserve resources through better design and production processes and facilitate the re-use and recycling of used packaging materials.
Here you can view Aspen Australia's plan and report.
UPDATE: Important Information regarding Di-gesic and Doloxene.
Australian News, Media Release
UPDATE: We wish to advise you that the Administrative Appeals Tribunal (AAT) has granted Aspen Australia’s application to stay the cancellation of products containing dextropropoxyphene (Di-Gesic and Doloxene) from the ARTG. This allows us the opportunity to have our appeal of the Therapeutic Goods Administration’s (TGA) decision to cancel the registrations heard by the AAT.
South China Morning Post Article
Australian News, New Zealand News, Media Release
In a span of 11 years, Aspen Pharmacare Australia has become one of Australia's leading pharmaceutical companies, developing a reputation for reliable, regulated and affordable medicines. Aspen-marketed brands account for one out of seven prescriptions written in the country.
Business Review Australia Article
Australian News, New Zealand News, Media Release
Aspen Pharmacare Australia Expanding Global Business - from recent acquisition to expansion plans in Asia, Aspen Pharmacare Australia is ready to increase sales and markets.
Aspen Pharmacare Australia announces a new partnership with Eli Lilly Australia for Zyprexa®
Australian News, Announcements
Aspen Pharmacare Australia Pty Ltd (Aspen) is pleased to announce a new partnership with Eli Lilly Australia (Lilly) for Zyprexa® (olanzapine), a market leading medication for schizophrenia and bipolar disorder
Aspen Acquires Sigma's Pharmaceutical Business For AU$900 Million
Australian News, New Zealand News, Media Release
Aspen, South Africa's leading pharmaceutical company, has announced that all conditions precedent have been met for it to acquire the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited.
Formal Agreement Reached for $900 Million Sale of Pharmaceuticals Division to Aspen Pharmacare
Australian News, Announcements
On 16 August 2010, Sigma announced that it had agreed in principle to sell its Pharmaceuticals Division to the Aspen Pharmacare Holdings Limited group of companies for A$900 million.
Aspen to distribute Merck products
Australian News, Announcements
Effective immediately, Aspen is taking over the sales, distribution and marketing of a portfolio of dermatology products from Merck, with estimated annual sales of $50 million.
